Phase 3 N=60 Bupropion and Restless Legs Syndrome
Restless Legs Syndrome
Primary: Change in International Restless Legs Syndrome Study Group (IRLSSG) Severity Scale. — -10.4; -7.6; -10.8; -6.0 points on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=370 Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People
Influenza
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) — 1; 0; 0; 0 Participants
Phase 3 N=334 A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Modified Total Sharp X-Ray Score at Week 26 — 1.5; 2.4 units on a scale — p=<0.001
Phase 3 N=371 A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects
Head Lice
Primary: Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 71…
Phase 3 N=35 A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome
Clinically Isolated Syndrome
Primary: Time in Month to Clinical Definite Multiple Sclerosis (CDMS) From Kaplan-Meier Estimates — 15.6; 17.0 Month
Phase 3 N=83 Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis
Ulcerative Colitis
Primary: Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population — 56.1; 55.0 % participants with treatment success…
Phase 3 N=410 A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation
Head Lice
Primary: Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 76…
Phase 3 N=147 SSRI and Buprenorphine
Opiate Dependence · Depression
Primary: Percentage of Participants Who Dropped Out of Buprenorphine Treatment — 33.3; 44.0 percentage of participants — p=.19
Phase 3 N=217 Effects of SH T00658ID on Libido
Contraception · Libido
Primary: Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS) — 6.45; 5.98 scores on a scale
Phase 3 N=33 The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics
Periodontal Disease
Primary: HbA1c Levels in Blood — 9.47; 10.27 Percentage — p=0.05
Phase 3 N=421 Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
Psoriasis
Primary: Participant Satisfaction With Injection Device Evaluated at Week 12 for Modified Intent-to-treat (mITT) Population — 8.9; 7.6 units on a scale — p=<0.001
Phase 3 N=224 Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic
Chronic Pain · Osteoarthritis
Primary: The Primary Endpoint is Defined as the Change From Week -1 of the Average Pain Intensity Score on an 11-point NRS-3 at Week 6. — -3.4 Units on a scale
Phase 3 N=474 Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Clinical Resolution — 89; 62 eyes
Phase 3 N=48 Caverject User Study
Erectile Dysfunction
Primary: Percentage of Participants Who Successfully Operated the Caverject Impulse Delivery System — 95.83 percentage of participants
Phase 3 N=423 Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)
Diabetes Mellitus, Type 2 · Renal Insufficiency, Chronic
Primary: Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 54 — 7.76; 7.79; -0.70; -0.62 Percent of glycosylated hemoglobin